英文名稱(chēng) | Nintedanib | BIBF 1120 | Intedanib |
---|---|
中文名稱(chēng) | 尼達(dá)尼布 |
CAS號(hào) | 656247-17-5 |
分子式 | C31H33N5O4 |
分子量 | 539.62 |
外觀 | Yellow crystalline powder |
規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專(zhuān)享價(jià) | 數(shù)量 |
---|---|---|---|---|
500 mg | In-stock | ¥500.00 | 登錄后可見(jiàn) | |
1 g | In-stock | ¥850.00 | 登錄后可見(jiàn) |
英文名稱(chēng) | Nintedanib | BIBF 1120 | Intedanib |
---|---|
中文名稱(chēng) | 尼達(dá)尼布 |
CAS號(hào) | 656247-17-5 |
分子式 | C31H33N5O4 |
分子量 | 539.62 |
外觀 | Yellow crystalline powder |
Nintedanib, also known as BIBF 1120, is an orally bioavailable inhibitor of vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet derived growth factor receptor (PDGFR). Intedanib selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, which may result in the induction of endothelial cell apoptosis; a reduction in tumor vasculature; and the inhibition of tumor cell proliferation and migration
PMID: 19522465 DOI: 10.1021/jm900431g
Cancer Res, 2008, 68(12), 4774-4782.